The Technical Analyst
TFF Pharmaceuticals Inc [TFFP]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
TFF Pharmaceuticals Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-8.57% $3.52
America/New_York / 15 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 8.87 mill |
| EPS: | -11.85 |
| P/E: | -0.300 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 2.52 mill |
| Avg Daily Volume: | 0.0296 mill |
| RATING 2024-04-15 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.300 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.05x |
| Company: PE -0.300 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$5.58 (58.44%) $2.06 |
| Date: 2024-04-15 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.39 - 4.51 ( +/- 30.75%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-12-13 | King Thomas Braxton | Buy | 132 442 | Stock Options (Right to Buy) |
| 2023-12-11 | King Thomas Braxton | Buy | 0 | |
| 2023-12-01 | Roberts Brandi | Buy | 52 858 | Stock Options (Right to Buy) |
| 2023-12-01 | Mills Robert S | Buy | 52 858 | Stock Options (Right to Buy) |
| 2023-12-01 | Rocamboli Stephen | Buy | 52 858 | Stock Options (Right to Buy) |
| INSIDER POWER |
|---|
| 69.76 |
| Last 95 transactions |
| Buy: 4 763 088 | Sell: 2 981 910 |
Forecast:
16:00 - $3.50
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $3.50
Forecast 2: 16:00 - $3.50
Forecast 3: 16:00 - $3.50
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.52 (-8.57% ) |
| Volume | 0.0321 mill |
| Avg. Vol. | 0.0296 mill |
| % of Avg. Vol | 108.44 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TFFP
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
TFFP
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various pain; Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.
Latest Press Releases
2024-04-15 07:00:00 - Press Release
Tff Pharmaceuticals Announces Additional Positive Data From The Tacrolimus Inhalation Powder (tff Tac) Phase 2 Trial Following Oral Presentation At The Ishlt 44th Annual Late Breaking Clinical Science Abstract Sessions
New gene expression analysis from ongoing phase 2 study provides strong biomarker evidence that treatment with tff tac results in normalization of rejection-related genes
2024-03-28 16:05:00 - Press Release
Tff Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results
Fort worth, texas, march 28, 2024 (globe newswire) -- tff pharmaceuticals, inc. (nasdaq: tffp) (“the company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented thin film freezing (tff) technology platform, today reported financial results for the fourth quarter and full year 2023.
2024-03-27 16:01:00 - Press Release
Tff Pharmaceuticals Announces Updated Data From The Tacrolimus Inhalation Powder (tff Tac) And Voriconazole Inhalation Powder (tff Vori) Clinical Programs
Eight of eight patients successfully transitioned from oral tacrolimus to tff tac with no sign of acute rejection at reduced systemic exposures
2024-03-25 09:01:00 - Press Release
Tff Pharmaceuticals Announces Oral Presentation Of Interim Data From The Phase 2 Study Of Tacrolimus Inhalation Powder (tff Tac) For The Prevention Of Lung Transplant Rejection At The 44th Annual International Society For Heart And Lung Transplantation (ishlt) 2024 Meeting
Oral presentation to present updated data from phase 2 trial demonstrating successful transition of patients from oral tacrolimus to tff tac oral presentation to present updated data from phase 2 trial demonstrating successful transition of patients from oral tacrolimus to tff tac
2024-03-22 15:11:00 - Press Release
Tff Pharmaceuticals Announces Closing Of $1.2 Million Registered Direct Offering Priced At-the-market Under Nasdaq Rules
Fort worth, texas, march 22, 2024 (globe newswire) -- tff pharmaceuticals, inc (nasdaq: tffp) (the “company” or “tff pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented thin film freezing (tff) technology platform, today announced the closing of its previously announced registered direct offering priced at-the-market under nasdaq rules for the purchase and sale of 147,500 shares of common stock at a purchase price of $8.00 per share. in a concurrent private placement, the company also issued unregistered warrants to purchase up to 147,500 shares of common stock at an exercise price of $8...
Latest News
2024-01-24 08:00:00 - GlobeNewsWire
TFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Invasive Pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis Conference
FORT WORTH, Texas, Jan. 24, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that the Company will present data from the Phase 2 trial of Voriconazole Inhalation Powder (TFF VORI) for the treatment of invasive pulmonary aspergillosis at the upcoming Advances Against Aspergillosis & Mucormycosis (AAAM) Conference, which will be held from January 25-27, 2024, in Milan, Italy. Data being presented at the AAAM Conference were first disclosed by the Company in December 2023.
2023-12-18 16:01:00 - GlobeNewsWire
TFF Pharmaceuticals to Host Webcast and Conference to Review Initial Data from the Ongoing Phase 2 Trials of TFF VORI and TFF TAC
Company to host conference call and webcast on Tuesday, December 19th at 8:30 am ET Company to host conference call and webcast on Tuesday, December 19th at 8:30 am ET
2023-11-27 07:00:00 - GlobeNewsWire
TFF Pharmaceuticals to Participate in the 2023 Benchmark Discovery One-on-One Investor Conference – December 7, 2023
FORT WORTH, Texas, Nov. 27, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that company management will be participating in the 2023 Benchmark Discovery One-on-One Investor Conference being held December 7, 2023 at the New York Athletic Club in New York City. The company has two products in Phase 2 development and continues to guide for a December release of interim data from both studies.
2023-11-14 20:23:02 - Seeking Alpha
TFF Pharmaceuticals, Inc. (TFFP) Q3 2023 Earnings Call Transcript
TFF Pharmaceuticals, Inc. (NASDAQ:TFFP ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Corey Davis - IR, LifeSci Advisors Harlan Weisman - CEO Zamaneh Mikhak - Chief Medical Officer Kirk Coleman - CFO Conference Call Participants Jonathan Aschoff - ROTH MKM Justin Walsh - JonesTrading Daniel Carlson - Tailwinds Operator Good afternoon, ladies and gentlemen, and welcome to the TFF Pharmaceuticals Third Quarter 2023 Corporate Update and Earnings Conference Call. As a reminder, this conference is being recorded.
2023-11-07 16:05:00 - GlobeNewsWire
TFF Pharmaceuticals to Hold Third Quarter 2023 Financial and Business Results Conference Call on November 14, 2023
Company to hold conference call and webcast on November 14, 2023, at 4:30 PM ET Company to hold conference call and webcast on November 14, 2023, at 4:30 PM ET
2023-09-28 16:29:00 - GlobeNewsWire
TFF Pharmaceuticals to Participate in Upcoming Investor Conferences
FORT WORTH, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced that CEO Harlan Weisman, M.D. will attend and hold one-on-one investor meetings at the upcoming Jones Trading 2023 Healthcare Summit. Dr. Weisman will also present and hold one-on-one investor meetings at the upcoming Roth MKM 2023 Healthcare Opportunities Conference.
2023-08-23 07:00:00 - GlobeNewsWire
TFF Pharmaceuticals to Participate in the H.C. Wainwright 25th Annual Global Investment Conference – September 11-13, 2023
FORT WORTH, Texas, Aug. 23, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that CEO Harlan Weisman, M.D. will be presenting a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. Company management will also be participating in one-on-one meetings during the conference.
2023-08-17 12:16:09 - PennyStocks
10 Top Penny Stocks To Buy According To Insiders In August
Engaging in the world of low-cost stocks often referred to as penny stocks, is appealing to those looking to capitalize on the potential upsides of the stock market. These stocks, priced below $5, are known for their intrinsic risk.
2023-08-16 12:25:55 - PennyStocks
7 Penny Stocks To Buy According To Insiders In August
Investing in penny stocks represents an enticing prospect for those seeking to leverage the stock market's potential gains. Characterized by an inherent risk and the promise of significant rewards, these under-$5 shares often become the subjects of speculation.
2023-08-15 14:26:44 - PennyStocks
4 Penny Stocks To Buy According To Insiders In August
Penny stocks provide a captivating opportunity for those aiming to profit in the stock market. The intrinsic risk and potential rewards associated with these stocks often lead to intense speculation and a quest for remarkable profits.